F
Filip Dubovsky
Researcher at MedImmune
Publications - 67
Citations - 4153
Filip Dubovsky is an academic researcher from MedImmune. The author has contributed to research in topics: Immunogenicity & Malaria vaccine. The author has an hindex of 33, co-authored 60 publications receiving 3608 citations. Previous affiliations of Filip Dubovsky include PATH & AstraZeneca.
Papers
More filters
Journal ArticleDOI
Efficacy of the RTS,S/AS02A vaccine against Plasmodium falciparum infection and disease in young African children: randomised controlled trial
Pedro L. Alonso,Jahit Sacarlal,John J. Aponte,Amanda J. Leach,Eusebio Macete,Jessica Milman,Inacio Mandomando,Bart Spiessens,Caterina Guinovart,Mateu Espasa,Quique Bassat,Pedro Aide,Opokua Ofori-Anyinam,Margarita M. Navia,Sabine Corachan,Marc Ceuppens,Marie-Claude Dubois,Marie-Ange Demoitié,Filip Dubovsky,Clara Menendez,Nadia Tornieporth,W. Ripley Ballou,Ricardo Thompson,Joe Cohen +23 more
TL;DR: The results show development of an effective vaccine against malaria is feasible and the RTS,S/AS02A vaccine was safe, well tolerated, and immunogenic.
Journal ArticleDOI
Duration of protection with RTS,S/AS02A malaria vaccine in prevention of Plasmodium falciparum disease in Mozambican children: single-blind extended follow-up of a randomised controlled trial
Pedro L. Alonso,Jahit Sacarlal,John J. Aponte,Amanda J. Leach,Eusebio Macete,Pedro Aide,Betuel Sigaúque,Jessica Milman,Inacio Mandomando,Quique Bassat,Caterina Guinovart,Mateu Espasa,Sabine Corachan,Marc Lievens,Margarita M. Navia,Marie-Claude Dubois,Clara Menéndez,Filip Dubovsky,Joe Cohen,Ricardo Thompson,W. Ripley Ballou +20 more
TL;DR: Results show that RTS,S/AS02A confers partial protection in African children aged 1-4 years living in rural endemic areas against a range of clinical disease caused by P falciparum for at least 18 months, and confirm the potential of malaria vaccines to become credible control tools for public-health use.
Journal ArticleDOI
Blood stage malaria vaccine eliciting high antigen-specific antibody concentrations confers no protection to young children in Western Kenya.
Bernhards Ogutu,Odika J. Apollo,Denise McKinney,Willis Okoth,Joram Siangla,Filip Dubovsky,Kathryn Tucker,John N. Waitumbi,Carter L. Diggs,Janet Wittes,Elissa Malkin,Amanda J. Leach,Lorraine Soisson,Jessica Milman,Lucas Otieno,Carolyn A. Holland,Mark E. Polhemus,Shon Remich,Christian F. Ockenhouse,Joe Cohen,W. Ripley Ballou,Samuel K. Martin,Evelina Angov,V. Ann Stewart,Jeffrey A. Lyon,D. Gray Heppner,Mark R. Withers +26 more
TL;DR: FMP1/AS02 had a good safety profile and was well-tolerated but more reactogenic than the comparator, and is not a promising candidate for further development as a monovalent malaria vaccine.
Journal ArticleDOI
Single-Dose Nirsevimab for Prevention of RSV in Preterm Infants.
M. Pamela Griffin,Yuan Yuan,Therese Takas,Joseph B. Domachowske,Shabir A. Madhi,Paolo Manzoni,Eric A. F. Simões,Mark T. Esser,Anis A. Khan,Filip Dubovsky,Tonya Villafana,John P. DeVincenzo +11 more
TL;DR: A single injection of nirsevimab resulted in fewer medically attended RSV-associated lower respiratory tract infections and hospitalizations than placebo throughout the RSV season in healthy preterm infants.
Journal ArticleDOI
Safety, Tolerability and Pharmacokinetics of MEDI8897, an Extended Half-life Single-dose Respiratory Syncytial Virus Prefusion F-targeting Monoclonal Antibody Administered as a Single Dose to Healthy Preterm Infants.
Joseph B. Domachowske,Anis A. Khan,Mark T. Esser,Kathryn Jensen,Therese Takas,Tonya Villafana,Filip Dubovsky,M. Pamela Griffin +7 more
TL;DR: The extended half-life of MEDI8897 and RSV-neutralizing activity support protection from RSV for the duration of a typical 5-month season after a single 50 mg intramuscular (IM) dose are demonstrated.